AKR1A1 Variant Associated With Schizophrenia Causes Exon Skipping, Leading to Loss of Enzymatic Activity
-
Published:2021-12-06
Issue:
Volume:12
Page:
-
ISSN:1664-8021
-
Container-title:Frontiers in Genetics
-
language:
-
Short-container-title:Front. Genet.
Author:
Iino Kyoka,Toriumi Kazuya,Agarie Riko,Miyashita Mitsuhiro,Suzuki Kazuhiro,Horiuchi Yasue,Niizato Kazuhiro,Oshima Kenichi,Imai Atsushi,Nagase Yukihiro,Kushima Itaru,Koike Shinsuke,Ikegame Tempei,Jinde Seiichiro,Nagata Eiichiro,Washizuka Shinsuke,Miyata Toshio,Takizawa Shunya,Hashimoto Ryota,Kasai Kiyoto,Ozaki Norio,Itokawa Masanari,Arai Makoto
Abstract
Schizophrenia is a heterogeneous psychiatric disorder characterized by positive symptoms such as hallucinations and delusions, negative symptoms such as anhedonia and flat affect, and cognitive impairment. Recently, glucuronate (GlucA) levels were reported to be significantly higher in serum of patients with schizophrenia than those in healthy controls. The accumulation of GlucA is known to be related to treatment-resistant schizophrenia, since GlucA is known to promote drug excretion by forming conjugates with drugs. However, the cause of GlucA accumulation remains unclear. Aldo-keto reductase family one member A1 (AKR1A1) is an oxidoreductase that catalyzes the reduction of GlucA. Genetic loss of AKR1A1 function is known to result in the accumulation of GlucA in rodents. Here, we aimed to explore genetic defects in AKR1A1 in patients with schizophrenia, which may result in the accumulation of GlucA. We identified 28 variants of AKR1A1 in patients with schizophrenia and control subjects. In particular, we identified a silent c.753G > A (rs745484618, p. Arg251Arg) variant located at the first position of exon 8 to be associated with schizophrenia. Using a minigene assay, we found that the c.753G > A variant induced exon 8 skipping in AKR1A1, resulting in a frameshift mutation, which in turn led to truncation of the AKR1A1 protein. Using the recombinant protein, we demonstrated that the truncated AKR1A1 completely lost its activity. Furthermore, we showed that AKR1A1 mRNA expression in the whole blood cells of individuals with the c.753G > A variant tended to be lower than that in those without the variants, leading to lower AKR activity. Our findings suggest that AKR1A1 carrying the c.753G > A variant induces exon skipping, leading to a loss of gene expression and enzymatic activity. Thus, GlucA patients with schizophrenia with the c.753G > A variant may show higher GlucA levels, leading to drug-resistant schizophrenia, since drug excretion by GlucA is enhanced.
Funder
Japan Society for the Promotion of Science
Japan Agency for Medical Research and Development
Kanae Foundation for the Promotion of Medical Science
Takeda Science Foundation
Uehara Memorial Foundation
Sumitomo Foundation
SENSHIN Medical Research Foundation
Japan Science and Technology Agency
Center for Integrative Science of Human Behavior, University of Tokyo
International Research Center for Neurointelligence, University of Tokyo
Publisher
Frontiers Media SA
Subject
Genetics (clinical),Genetics,Molecular Medicine
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献